This refresh
Data-driven refresh September 28, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,241 tickers); 1,704 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top 30 — quality compounders at a fair price
1. DLO — DLocal Limited · score 89.1
Software - Infrastructure · price $13.82 · 1Y $18.80 · 5Y $27.53 · 10Y $40.83
FCF $413m C · Rev +46.6% A · D/E 0.12 B+ · P/E 20.3x B+ · PEG 0.59 A-
Why now. Software - Infrastructure · market cap $4.1b. 18% off the 52-week high of $16.78. Revenue growing +47% — in hypergrowth territory. PEG 0.59 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $18.80 (implying +36% upside).
Moat. Net margin 18% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Free cash flow runs well ahead of reported net income.
Risk. Software — competitive moat is durable until it isn't; watch net revenue retention, gross margin trends, and any new market entrant with a fundamentally lower price point.
Horizon. 1-3 yr $18.80 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $27.53 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $40.83 if current growth sustains into durable earnings power.
2. ADBE — Adobe Inc. · score 88.8
Software - Application · price $231.01 · 1Y $278.15 · 5Y $407.25 · 10Y $604.12
FCF $10.6b A- · Rev +12.0% B+ · D/E 0.58 C+ · P/E 12.9x A · PEG 0.57 A-
Why now. Software - Application · market cap $91.8b. Down 36% from 52-week high of $363.70 — deep drawdown territory. Revenue growing +12%, comfortably above the S&P median. PEG 0.57 — paying under fair value for the growth rate. 33 sell-side analysts rate this a Hold with a mean 1-yr target of $278.15 (implying +20% upside).
Moat. Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 62% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 145% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 36% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.42 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Software — competitive moat is durable until it isn't; watch net revenue retention, gross margin trends, and any new market entrant with a fundamentally lower price point.
Horizon. 1-3 yr $278.15 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $407.25 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $604.12 if current growth sustains into durable earnings power.
3. NBIX — Neurocrine Biosciences, Inc. · score 87.6
Drug Manufacturers - Specialty & Generic · price $140.44 · 1Y $208.40 · 5Y $305.11 · 10Y $452.62
FCF $870m C+ · Rev +34.4% A · D/E 0.12 B+ · P/E 20.5x B+ · PEG 0.28 A
Why now. Neurocrine Biosciences is a compelling growth story trading at a significant discount to its underlying potential, driven by robust demand for its specialized neurological and endocrine treatments. The Bull Rankings model assigns a Growth pillar score of 96/100, its strongest pillar, reflecting the impressive 34.4% TTM revenue growth. Despite this rapid expansion, the stock trades at an exceptionally low PEG ratio of 0.28, indicating the market is underpricing its future earnings power, particularly from commercial products like INGREZZA. Our reverse DCF further supports this, showing the current price implies a mere 6% FCF growth in year one, far below recent performance, signaling substantial pessimism is priced in. The thesis rests on the continued strong adoption and pipeline expansion of its high-value pharmaceutical portfolio.
Moat. Neurocrine Biosciences' durable edge is rooted in its specialized portfolio of commercialized pharmaceuticals, such as INGREZZA for tardive dyskinesia and CRENESSITY for congenital adrenal hyperplasia, targeting niche, high-barrier neurological and endocrine disorders. The company's continuous investment in discovering and developing new treatments, exemplified by candidates like NBI-1076986 for movement disorders, establishes a strong intellectual property moat and significant regulatory hurdles for potential competitors. This focus on specialized, high-need markets underpins the Bull Rankings model's signal of "Durable high returns."
Risk. The primary bear case against Neurocrine Biosciences centers on potential execution risk within its clinical pipeline and the impact of shareholder dilution. While the Bull Rankings model's Quality pillar, at 81/100, is robust, it is the softest of its three pillars, suggesting areas where operational excellence or market positioning could face challenges if not carefully managed. Our model also signals "Diluting shareholders (caution)," indicating a potential drag on per-share value if the company continues to issue equity. A concrete signal confirming the bear case would be a significant clinical trial failure for a late-stage candidate like Osavampator for major depressive disorder, or a sustained deceleration in revenue growth below the current 34.4%, which would invalidate the current valuation.
Horizon. 1-3 yr $208.40 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $305.11 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $452.62 if current growth sustains into durable earnings power.
4. HRMY — Harmony Biosciences Holdings, Inc. · score 86.9
Biotechnology · price $40.01 · 1Y $47.36 · 5Y $69.35 · 10Y $102.87
FCF $355m C · Rev +24.3% A- · D/E 0.16 B+ · P/E 12.9x A- · PEG 0.46 A
Why now. The bull case hinges on WAKIX’s dominant position in narcolepsy, a rare neurological market where the drug’s novel mechanism drives outsized pricing power. The business is delivering 18.9% profit margin, 18.1% ROE and 24.3% revenue growth YoY, all while trading at a cheap PE of 12.9 versus peers. The thesis rests on compounding this high‑margin growth as Phase‑3 and Phase‑2 trials expand the pitolisant franchise.
Moat. WAKIX’s FDA‑approved status and unique histamine‑H3 antagonism create a high switching cost for patients and prescribers, locking in a captive narcolepsy base that competitors can’t replicate quickly. The 18.1% ROE reflects pricing power derived from this category leadership and the company’s low debt‑to‑equity of 0.16, enabling reinvestment without dilution.
Risk. The bear case centers on the looming revenue slowdown implied by the reverse‑DCF, which assumes free‑cash‑flow growth falling to -17% in year 1 and only 3% by year 10—well below the current 24.3% top‑line growth. If trial readouts falter or the high‑dose/GR formulations fail to launch, the PE of 12.9 could balloon as earnings compress, confirming the downside.
Horizon. 1-3 yr $47.36 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $69.35 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $102.87 if current growth sustains into durable earnings power.
5. INTU — Intuit Inc. · score 85.5
Software - Application · price $269.40 · 1Y $405.60 · 5Y $593.84 · 10Y $880.92
FCF $8.7b B+ · Rev +13.9% B+ · D/E 0.44 B · P/E 16.4x A- · PEG 0.88 B+
Why now. Intuit’s moat is anchored by QuickBooks, the dominant financial‑management platform for the U.S. SMB market, driving a 13.9% revenue growth YoY and delivering a 21.3% profit margin. The business’s free cash flow of $8.7 B underpins a 24% ROE, giving management the flexibility to buy back shares and raise the dividend – signals our model flags as upside catalysts. The thesis rests on the fact that QuickBooks’ sticky subscription base will keep compounding earnings at a rate that outpaces the modest -10% year‑1 growth implied by the reverse‑DCF, making the current price a bargain.
Moat. QuickBooks and Mailchimp create a high‑switching‑cost ecosystem for small‑ and mid‑market businesses, locking in recurring revenue and enabling cross‑sell of payroll, payments, and financing. The 24% ROE reflects pricing power derived from category leadership in SMB financial software, a position competitors can’t replicate quickly without massive integration costs.
Risk. The stock trades at a forward P/E of 16.4, but the reverse‑DCF assumes a -10% FCF growth rate in year 1, signaling that investors may be over‑optimistic about sustaining current margins if competitive pressure from integrated ERP suites intensifies. A breach of the 52‑week low ($252.84) would confirm margin compression and could force management to pause buybacks, eroding the upside narrative.
Horizon. 1-3 yr $405.60 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $593.84 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $880.92 if current growth sustains into durable earnings power.
6. NVDA — NVIDIA Corporation · score 85
Semiconductors · price $228.86 · 1Y $327.70 · 5Y $479.79 · 10Y $711.73
FCF $127.0b A · Rev +83.4% A · D/E 0.17 B+ · P/E 29.0x B · PEG 0.47 A
Why now. NVIDIA’s AI data‑center dominance fuels relentless compounding – the Compute & Networking segment is delivering 83.4% revenue growth YoY while the business generates $127.0 b free cash flow and enjoys a 63.7% profit margin. With a PEG of 0.47 and a PE of 29, the market is already pricing in a 48% FCF growth rate that is below the actual revenue surge, meaning the upside is still under‑appreciated. The thesis rests on sustained AI‑driven demand in data centers, which will keep compounding earnings for years to come.
Moat. NVIDIA’s moat lies in its proprietary GPU architecture and AI software stack that power the Compute & Networking segment, locking in hyperscale cloud providers and enterprise customers who face massive switching costs. The 84.2% ROE reflects pricing power from category leadership in AI accelerators, a barrier competitors struggle to match due to the depth of NVIDIA’s IP and ecosystem.
Risk. The bear case centers on the lofty valuation – a PE of 29 for a megacap with a beta of 2.22 signals market sensitivity, and the reverse‑DCF implies growth will taper to just 3% by year 10, far slower than the current 83.4% revenue surge. A slowdown in data‑center spend or a disruptive AI chip from a rival would force the multiple down, confirming the risk.
Horizon. 1-3 yr $327.70 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $479.79 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $711.73 if current growth sustains into durable earnings power.
7. GDDY — GoDaddy Inc. · score 84.6
Software - Infrastructure · price $93.71 · 1Y $106.75 · 5Y $156.29 · 10Y $231.85
FCF $1.7b C+ · Rev +7.4% B · D/E n/a · P/E 13.9x A- · PEG 0.53 A-
Why now. GoDaddy’s Websites + Marketing suite is fueling a resilient 7.4% revenue growth while delivering a solid 17.8% profit margin, underpinning a PE of 13.9x that signals attractive valuation; the Bull Rankings model awards a Quality score of 96, the strongest pillar, confirming the business’s operational excellence, and the thesis hinges on the continued expansion of its A&C segment’s subscription base.
Moat. The Applications & Commerce segment’s integrated website‑builder and Managed WordPress platform lock small‑business owners into a sticky ecosystem where switching costs are high because of built‑in SEO tools, branding assets, and e‑commerce capabilities that competitors can’t replicate overnight.
Risk. The reverse‑DCF shows the market pricing a -15% FCF growth rate in year 1, far below the trailing 7.4% revenue growth, implying pessimism that could be validated if margin pressure or competitive pricing erodes the current 17.8% profit margin; a sustained drop below the 13.9x PE would trigger a sell‑off.
Horizon. 1-3 yr $106.75 (analyst consensus (n=16)) — fundamentals + valuation re-rating. 5 yr $156.29 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $231.85 if current growth sustains into durable earnings power.
8. APP — AppLovin Corporation · score 83.8
Advertising Agencies · price $308.24 · 1Y $498.37 · 5Y $729.66 · 10Y $1,082
FCF $4.5b B · Rev +60.6% A · D/E 1.11 C+ · P/E 23.7x C+ · PEG 0.67 A-
Why now. The bull case hinges on MAX, AppLovin's AI‑driven in‑app bidding platform, which is rapidly capturing premium publisher inventory and fueling explosive top‑line expansion. The business is delivering 60.6% revenue growth YoY while preserving a 64.6% profit margin, generating $4.5 B of free cash flow—a rare cash‑rich profile for a growth‑stage megacap. Our Bull Rankings model rates the company 83.8/100, with Growth as its strongest pillar, confirming that the compounding engine is real and sustainable, and the thesis rests on MAX’s ability to keep scaling this high‑margin growth.
Moat. MAX creates a durable moat through real‑time, AI‑powered auctions that lock in publishers by delivering higher eCPMs than any static waterfall, making switching costly. Coupled with Adjust’s measurement suite, AppLovin offers an end‑to‑end stack that embeds deep data insights, locking developers into a single platform for acquisition, monetization, and analytics—an integration competitors struggle to replicate quickly.
Risk. The bear case centers on the lofty valuation implied by a P/E of 23.7 and a beta of 2.49, which magnifies any slowdown in growth; the reverse‑DCF assumes free‑cash‑flow growth decelerating to 3% by year 10, far below the current 60.6% revenue surge, indicating the market may be pricing in a sharp earnings slowdown. A miss on MAX’s rollout or a macro‑ad spend contraction that pushes revenue growth below 30% would validate the risk and collapse the upside.
Horizon. 1-3 yr $498.37 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $729.66 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $1,082 if current growth sustains into durable earnings power.
9. CARG — CarGurus, Inc. · score 83
Internet Content & Information · price $30.81 · 1Y $42.00 · 5Y $61.49 · 10Y $91.22
FCF $315m C · Rev +13.9% B+ · D/E 0.70 B · P/E 15.9x B+ · PEG 0.67 A-
Why now. CarGurus’ Digital Deal platform is unlocking online‑first car purchases, letting the company capture higher‑margin subscription fees from dealers while scaling its audience. The business is delivering 13.9% revenue growth, 18.2% profit margin and 66.6% ROE, all at a modest P/E of 15.9x—a rare quality‑growth combo that our model rewards with an 86‑point Quality score. The thesis rests on the continued compounding of Digital Deal adoption, which should keep growth above the market’s modest expectations.
Moat. The integrated dealer‑subscription ecosystem creates a sticky network: dealers pay recurring fees to access CarGurus’ massive shopper base, and the Digital Deal workflow locks consumers into the platform from browse to finance. This high‑frequency, data‑rich relationship fuels pricing power, evident in the 66.6% ROE, and is difficult for new entrants to replicate quickly.
Risk. The Bull Rankings model flags a Value pillar of 78, meaning the stock already trades on the cheap side of peers, but the reverse‑DCF shows the market assumes a negative -6% FCF growth in year 1 versus the actual 13.9% revenue expansion—signaling that investors are pricing in a slowdown. A higher‑beta (1.16) and a debt‑to‑equity of 0.7 could amplify any macro‑driven dip in auto demand, and a breach of the implied growth trajectory would trigger a sell‑off.
Horizon. 1-3 yr $42.00 (analyst consensus (n=12)) — fundamentals + valuation re-rating. 5 yr $61.49 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $91.22 if current growth sustains into durable earnings power.
10. DOCS — Doximity, Inc. · score 82.7
Health Information Services · price $26.20 · 1Y $29.94 · 5Y $43.84 · 10Y $65.04
FCF $306m C · Rev +11.2% B · D/E 0.01 A- · P/E 31.2x B · PEG 0.59 A-
Why now. The bull case hinges on Doximity’s AI‑driven workflow tool, Ask, which embeds evidence‑based content directly into clinicians’ daily routines, locking in a high‑engagement user base. That stickiness fuels a 25.5% profit margin, a 11.2% revenue growth rate and a $306 m free‑cash‑flow generation, all while the Bull Rankings model awards a stellar Quality pillar of 88 out of 100 (overall score 82.7). The thesis rests on the compounding power of this margin‑rich growth as the platform expands its AI suite.
Moat. Doximity’s moat derives from its integrated professional network and HIPAA‑compliant AI assistant, Ask, which creates a switching cost for physicians who rely on a single source for news, peer updates, and clinical decision support. The platform’s 18‑month average ROE of 18.2% reflects pricing power from being the de‑facto digital hub for U.S. doctors, a position hard for rivals to replicate without comparable data depth and compliance infrastructure.
Risk. The bear case centers on the elevated valuation: a forward P/E of 31.2 is well above the sector norm, and the Bull Rankings model flags Value as the softest pillar (score 76), indicating the stock trades on the cheap side of peers but still carries premium pricing. If revenue growth decelerates below the trailing 11.2% or the reverse‑DCF implied 9% cash‑flow growth proves optimistic, the high multiple could compress sharply. A sustained slowdown in user engagement with Ask would confirm this risk.
Horizon. 1-3 yr $29.94 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $43.84 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $65.04 if current growth sustains into durable earnings power.
11. EXLS — ExlService Holdings, Inc. · score 82.1
Information Technology Services · price $34.60 · 1Y $44.63 · 5Y $65.34 · 10Y $96.92
FCF $297m C · Rev +13.4% B+ · D/E 0.57 C+ · P/E 21.9x B+ · PEG 0.90 B+
Why now. EXLS’s AI‑driven insurance analytics platform is scaling at a 13.4% revenue clip while generating $297m of free cash flow and delivering a stellar 32.3% ROE, giving the business a high‑quality earnings engine. Our model’s strongest pillar – Growth – reflects this compounding top‑line momentum, and the 8‑year analyst consensus target of $44.63 already prices in a modest upside. The thesis rests on the continued capture of digital‑operations spend in the insurance segment, where AI‑enabled claims and underwriting services will keep the compounding engine humming.
Moat. The moat lives in EXLS’s deep integration with insurers’ core workflows – from claims management to actuarial risk analytics – creating high switching costs and pricing power that fuels its >30% ROE. Its AI‑enhanced data platform is a proprietary engine that rivals cannot replicate quickly, locking in long‑term contracts across the Insurance and Banking segments.
Risk. The price assumes a free‑cash‑flow growth of only ~4% versus the trailing 13.4% revenue surge, implying a valuation bias toward slower growth; the current P/E of 21.9 is elevated for a sector where peers trade nearer 15×, and a debt‑to‑equity of 0.57 adds balance‑sheet pressure. A slowdown in insurance spend or a margin dip below 11% would confirm the bear case and crush the upside.
Horizon. 1-3 yr $44.63 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $65.34 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $96.92 if current growth sustains into durable earnings power.
12. KTB — Kontoor Brands, Inc. · score 81.4
Apparel Manufacturing · price $64.93 · 1Y $97.50 · 5Y $142.75 · 10Y $211.76
FCF $422m C · Rev +34.3% A · D/E 2.06 C · P/E 13.1x A- · PEG 0.54 A-
Why now. Apparel Manufacturing · market cap $3.5b. Down 27% from 52-week high of $88.96 — deep drawdown territory. Revenue growing +34% — in hypergrowth territory. PEG 0.54 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $97.50 (implying +50% upside).
Moat. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 158% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. D/E 2.06 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer.
Horizon. 1-3 yr $97.50 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $142.75 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $211.76 if current growth sustains into durable earnings power.
13. CPAY — Corpay, Inc. · score 81.1
Software - Infrastructure · price $396.23 · 1Y $461.00 · 5Y $674.95 · 10Y $1,001
FCF $1.6b C+ · Rev +20.4% A- · D/E 2.75 D · P/E 24.1x B+ · PEG 0.76 A-
Why now. Corpay’s corporate‑payments platform is the engine, delivering cross‑border and virtual‑card spend management that fuels a 20.4% revenue growth rate and a 22.7% profit margin. Coupled with a PE of 24.1 and a PEG of 0.76, the business is expanding faster than its valuation assumes – the Bull Rankings model’s strongest pillar, Growth, signals that this compounding can persist. The thesis rests on the continued capture of enterprise expense‑management spend, which should keep the 20%+ growth trajectory alive.
Moat. The moat lives in Corpay’s integrated corporate‑payments suite – virtual cards, AP modernization and cross‑border solutions lock large enterprises into a single spend‑control ecosystem, creating high switching costs. That stickiness translates into a ROE of 32.2%, driven by pricing power in a market where few rivals can match the breadth of Corpay’s voucher, fleet‑fuel and lodging payment services.
Risk. The bear case hinges on the reverse‑DCF’s implied free‑cash‑flow growth of only ~3% versus the trailing 20.4% revenue surge, suggesting the market already discounts future acceleration. A debt‑to‑equity of 2.75 and a PE of 24.1 signal valuation pressure if growth decelerates, and any slowdown in corporate expense spend would immediately test the high‑growth premium. A breach of the 3% FCF growth assumption would confirm the downside.
Horizon. 1-3 yr $461.00 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $674.95 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $1,001 if current growth sustains into durable earnings power.
14. LRN — Stride, Inc. · score 80.9
Education & Training Services · price $76.66 · 1Y $88.16 · 5Y $129.07 · 10Y $191.47
FCF $433m C · Rev +4.7% C+ · D/E 0.33 A- · P/E 10.7x A · PEG 0.43 A
Why now. Stride’s end‑to‑end education platform for software engineering and healthcare curricula is locked into state‑customized contracts that drive recurring revenue, and the business is trading at a PE of 10.7 with a ROE of 20.7%—a rare combination of profitability and capital efficiency in ed‑tech. The platform’s $433 m of free‑cash‑flow supports ongoing buybacks, reinforcing the Bull Rankings model’s Value pillar (92) and underscoring the cheapness of the stock. The thesis rests on the platform’s ability to keep expanding state‑mandated curricula, compounding the modest 4.7% revenue growth into a durable earnings engine.
Moat. The platform’s single sign‑on, integrated learning‑management and data‑analytics suite creates high switching costs for state education agencies that have already built custom curricula on Stride’s system. This lock‑in fuels the 20.7% ROE by allowing pricing power in a niche where alternatives would require costly re‑integration of student data and compliance reporting.
Risk. The reverse‑DCF shows the market pricing a -13% FCF growth rate for the next year, far below the trailing 4.7% revenue growth, indicating investors expect a sharp slowdown; if state funding contracts tighten or new competitors crack the custom‑curriculum niche, the PE could re‑rate upward, eroding the cheap valuation. A breach of the 0.33 debt‑to‑equity ceiling with higher leverage would confirm the bear case.
Horizon. 1-3 yr $88.16 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $129.07 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $191.47 if current growth sustains into durable earnings power.
15. DECK — Deckers Outdoor Corporation · score 80.5
Footwear & Accessories · price $78.36 · 1Y $120.41 · 5Y $176.29 · 10Y $261.52
FCF $1.1b C+ · Rev +7.9% B · D/E 0.21 A- · P/E 11.1x A- · PEG 0.96 B+
Why now. Our Bull Rankings model gives DECK a Quality‑growth score of 80.5, anchored by a stellar Quality pillar (96). The premium HOKA performance‑running line is expanding in a market where revenue is already climbing 7.9% YoY, while the business converts that into an 18.4% profit margin and a blistering 44.1% ROE. With a PEG of 0.96 and a Value pillar at 73 (on the cheap side of peers), the stock is priced for a modest upside that rests on continued HOKA traction and the durable cash‑flow generation that fuels buybacks.
Moat. DECK’s moat lives in its premium‑priced, category‑leading footwear platforms—UGG’s iconic sheepskin boots, HOKA’s high‑performance running shoes, and Teva’s outdoor sandals—all sold through a deep retailer network that locks in shelf space and brand loyalty. The 44.1% ROE reflects pricing power derived from these differentiated product ecosystems, which competitors cannot replicate quickly without sacrificing brand equity.
Risk. The market is already pricing in a slowdown: the reverse‑DCF shows implied free‑cash‑flow growth of -4% in year 1, fading steadily to the low‑single‑digit range by year 10, well below the trailing 7.9% revenue growth. A higher beta of 1.15 amplifies downside if consumer spending on discretionary footwear wanes, and any miss on HOKA’s growth narrative would push the stock back toward its 52‑week low of $77.37. A sustained dip in margin or a miss on the implied growth trajectory would confirm the bear case.
Horizon. 1-3 yr $120.41 (analyst consensus (n=22)) — fundamentals + valuation re-rating. 5 yr $176.29 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $261.52 if current growth sustains into durable earnings power.
16. EPAM — EPAM Systems, Inc. · score 80.5
Information Technology Services · price $107.55 · 1Y $122.82 · 5Y $179.83 · 10Y $266.76
FCF $483m C · Rev +10.8% B · D/E 0.04 A- · P/E 14.6x A- · PEG 0.58 A-
Why now. Information Technology Services · market cap $5.5b. Down 52% from 52-week high of $222.53 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. PEG 0.58 — paying under fair value for the growth rate. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $122.82 (implying +14% upside).
Moat. ROE 11% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 120% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 52% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $122.82 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $179.83 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $266.76 if current growth sustains into durable earnings power.
17. LOPE — Grand Canyon Education, Inc. · score 80.5
Education & Training Services · price $146.40 · 1Y $195.00 · 5Y $285.50 · 10Y $423.52
FCF $243m C · Rev +7.0% C+ · D/E 0.16 A- · P/E 17.7x B · PEG 0.87 B+
Why now. Our model gives LOPE an 80.5/100 quality‑growth score, anchored by a stellar Quality pillar (97) that reflects its 33.5% ROE and 19.6% profit margin, while the softest Growth pillar (73) still signals solid upside. The company’s integrated learning‑management and counseling platform drives a steady 7% revenue expansion TTM, backed by free cash flow of $243 m and a modest debt‑to‑equity of 0.16. With a P/E of 17.7 and a consensus 1‑yr target of $195, the thesis rests on the durable cash‑generating engine of its education‑service suite compounding at double‑digit rates.
Moat. LOPE’s moat lies in its end‑to‑end education services—technology, curriculum, and counseling—that lock colleges into a single vendor for both administrative and academic functions, creating high switching costs. This integrated model fuels its 33.5% ROE by allowing pricing power across a captive university customer base that cannot easily replicate the combined LMS and enrollment support infrastructure.
Risk. The bear case focuses on the softest Growth pillar: the reverse‑DCF shows implied cash‑flow growth of –4% in year 1, well below the 7% revenue growth just delivered, indicating the market already prices in deceleration. A sustained slowdown would pressure the 17.7 P/E and could trigger a sell‑off, especially if the low‑beta (0.58) comfort fades and earnings miss expectations.
Horizon. 1-3 yr $195.00 (analyst consensus (n=3)) — fundamentals + valuation re-rating. 5 yr $285.50 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $423.52 if current growth sustains into durable earnings power.
18. PRDO — Perdoceo Education Corporation · score 80.1
Education & Training Services · price $30.01 · 1Y $34.51 · 5Y $50.53 · 10Y $74.96
FCF $221m C · Rev +11.7% B · D/E 0.11 A · P/E 10.9x A · PEG 0.62 A-
Why now. The bull case hinges on Perdoceo’s AIUS segment, which dominates online career‑oriented education for working adults and is fueling a 11.7% revenue growth while delivering a 20.6% profit margin and a 17.1% ROE. Our Bull Rankings model rates the company’s Quality at 90 — the strongest pillar — confirming that the business’s cash‑generating efficiency and low debt (0.11 D/E) are solid. Coupled with a cheap valuation (P/E 10.9, PEG 0.62) and a Value score of 75, the stock is priced on the cheap side of peers, making the upside hinge on sustaining this growth trajectory.
Moat. Perdoceo’s moat stems from its integrated online platform across CTU, AIUS and USAHS, which locks students into a seamless credentialing path and creates high switching costs for both learners and employers. The strong ROE of 17.1% reflects pricing power derived from being a leading provider in high‑demand fields like nursing, cybersecurity and health sciences, a position competitors can’t replicate quickly without comparable accreditation and scale.
Risk. The bear case is that the market already assumes a slowing free‑cash‑flow trajectory of –15% in year 1, well below the trailing 11.7% revenue growth, signaling pessimism that growth could stall. If AIUS enrollment softens or margin compression hits, the cheap P/E could turn into a value trap. A breach of the –15% FCF trend would confirm the downside and invalidate the quality narrative.
Horizon. 1-3 yr $34.51 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $50.53 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $74.96 if current growth sustains into durable earnings power.
19. RMD — ResMed Inc. · score 79.2
Medical Instruments & Supplies · price $222.10 · 1Y $250.22 · 5Y $366.35 · 10Y $543.46
FCF $1.6b C+ · Rev +9.9% B · D/E 0.13 B+ · P/E 21.3x B+ · PEG 1.29 B
Why now. Our model gives ResMed a Quality‑Growth score of 79.2 anchored by a stellar Quality pillar (90) and a solid Value pillar (67). The thesis hinges on the AirView cloud platform that locks hospitals, sleep clinics and home‑care providers into a data‑rich ecosystem, driving recurring revenue from the Sleep and Breathing Health segment. That ecosystem is underpinned by 9.9% revenue growth YoY, a 26.9% profit margin and $1.6 B of free cash flow, all of which fuel a sustainable compounding engine. The whole case rests on the ability to keep expanding AirView’s subscription base while margins stay high.
Moat. ResMed’s moat lives in its cloud‑connected AirView platform and the NightOwl disposable diagnostics that embed the company’s hardware into the patient workflow, creating high switching costs for sleep clinics and home‑care operators. The resulting pricing power, reflected in a 23.1% ROE, stems from category leadership in cloud‑enabled sleep apnea management that rivals can’t replicate without massive data and regulatory hurdles.
Risk. The bear case is that revenue growth could decelerate toward the 5% free‑cash‑flow growth implied by our reverse‑DCF, well below the current 9.9% pace, eroding the valuation cushion and pressuring the PE of 21.3. A slowdown would also shrink the cash‑flow runway needed to fund AirView expansion, and a sustained dip would trigger a sell‑off as investors reprice the growth story.
Horizon. 1-3 yr $250.22 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $366.35 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $543.46 if current growth sustains into durable earnings power.
20. DXCM — DexCom, Inc. · score 78.6
Medical Devices · price $86.68 · 1Y $94.48 · 5Y $138.33 · 10Y $205.20
FCF $1.4b C+ · Rev +15.5% B+ · D/E 0.53 B · P/E 34.3x C+ · PEG 1.33 B
Why now. DexCom’s G7 and G7 15‑Day CGM platforms are cementing its lead in the U.S. and overseas diabetes market, driving a 15.5% revenue growth and a 20.1% profit margin. Our Bull Rankings model gives DXCM a Quality‑growth score of 78.6, anchored by a strongest pillar of Quality, underscoring the durability of its pricing power and high 38.1% ROE. The thesis rests on the compounding effect of expanding CGM adoption across Type 1, Type 2 and pre‑diabetes patients, which should keep growth above 15% for years to come.
Moat. DXCM’s moat lies in its end‑to‑end CGM ecosystem – the G7 hardware, the Dexcom Share remote‑monitoring service and the Follow app – all prescribed by endocrinologists, creating high switching costs for patients and clinicians. Its 38.1% ROE reflects pricing power derived from category leadership in continuous glucose monitoring, a space where regulatory barriers and data integration make replication slow.
Risk. The stock trades at a lofty PE TTM of 34.3 and a beta of 1.42, implying market expectations are already baked in; the Bull Rankings model’s reverse‑DCF assumes a 23% FCF growth rate in year 1, far above the trailing 15.5% revenue growth, so any slowdown would expose the valuation. A breach of the 23% growth assumption would trigger a sell‑off, confirming the bear case.
Horizon. 1-3 yr $94.48 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $138.33 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $205.20 if current growth sustains into durable earnings power.
21. MELI — MercadoLibre, Inc. · score 78.3
Internet Retail · price $1712.41 · 1Y $2,272 · 5Y $3,327 · 10Y $4,935
FCF $12.4b A- · Rev +46.0% A · D/E 1.69 C+ · P/E 46.5x D · PEG 0.96 B+
Why now. Our model’s strongest pillar—Growth (98)—shows MELI’s Marketplace and Mercado Pago are still compounding at a blistering 46% revenue growth YoY, powered by a 23.8% ROE that reflects pricing power in Latin America’s e‑commerce frontier. The Bull Rankings model flags “durable high returns,” and with free cash flow of $12.4 B the business is cash‑rich while still expanding. Because the reverse‑DCF assumes a modest –9% to 3% FCF growth—well below the 46% top‑line pace—the market is pricing in pessimism, leaving the upside of the consensus 1‑yr target of $2,272.28 wide open.
Moat. MELI’s moat lives in its integrated ecosystem: the Marketplace drives traffic to Mercado Pago, which in turn fuels Mercado Crédito and Mercado Fondo, creating a self‑reinforcing loop that locks sellers and buyers into a single platform. This network effect yields a ROE of 23.8% as merchants pay for payment processing, credit, and logistics—services a new entrant cannot replicate without massive scale and regulatory clearance.
Risk. The stock trades at a lofty PE of 46.5 and a beta of 1.31, reflecting market expectations of continued rapid growth that may be hard to sustain; a debt‑to‑equity of 1.69 adds financial leverage risk if cash flows slow. If the reverse‑DCF’s implied FCF growth of –9% in year 1 materializes, the valuation collapses and the consensus 1‑yr target of $2,272.28 would be missed. A sustained margin compression or a slowdown in Marketplace traffic would confirm this bear case.
Horizon. 1-3 yr $2,272 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $3,327 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $4,935 if current growth sustains into durable earnings power.
22. YUMC — Yum China Holdings, Inc. · score 78.2
Restaurants · price $41.10 · 1Y $61.91 · 5Y $90.65 · 10Y $134.47
FCF $940m C+ · Rev +8.8% B · D/E 0.38 A- · P/E 15.1x B+ · PEG 0.90 B+
Why now. Yum China’s KFC franchise continues to dominate fast‑food dining in the world’s largest consumer market, driving an 8.8% revenue growth YoY while delivering a solid 7.8% profit margin and generating $940 m of free cash flow. Our Bull Rankings model rates the business at a 78.2 quality‑growth score, with Quality as the strongest pillar, underscoring the durability of its operating model. The thesis hinges on the ability of KFC, Pizza Hut and the expanding delivery platform to keep compounding cash generation well above the modest 4% growth baked into today’s price.
Moat. Yum China’s moat lies in its exclusive rights to the KFC and Pizza Hut brands across China, coupled with a proprietary digital delivery network that locks in millions of urban diners and creates high switching costs. The 18.2% ROE reflects pricing power from category leadership in quick‑service chicken and pizza, a lever competitors can’t replicate without the same brand licenses and logistics footprint.
Risk. The bear case centers on the price‑to‑earnings multiple of 15.1, which, while modest, already embeds a slowdown: the reverse‑DCF assumes cash‑flow growth of only 4% versus the 8.8% revenue growth just delivered, indicating the market may be pricing in a deceleration. A sustained dip in consumer spending or a failure to expand delivery penetration could push earnings lower, confirming the risk.
Horizon. 1-3 yr $61.91 (analyst consensus (n=20)) — fundamentals + valuation re-rating. 5 yr $90.65 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $134.47 if current growth sustains into durable earnings power.
23. BSX — Boston Scientific Corporation · score 77.8
Medical Devices · price $44.11 · 1Y $61.00 · 5Y $89.31 · 10Y $132.49
FCF $3.6b B · Rev +13.5% B+ · D/E 0.50 B · P/E 17.9x A- · PEG 0.62 A-
Why now. Boston Scientific’s leadership in the cardiovascular and MedSurg segments fuels a relentless pipeline of high‑margin, single‑use endoscopic devices – from SpyGlass to duodenoscopes – that underpins its 13.5% revenue growth, 17.5% profit margin and $3.6 B free‑cash‑flow. The Bull Rankings model flags Growth as its strongest pillar (88), meaning the business is delivering compounding top‑line expansion that will keep earnings accelerating. The thesis hinges on this durable, procedure‑driven demand continuing to compound earnings well beyond the modest 1‑yr consensus target.
Moat. The moat lives in the procedural lock‑in of Boston Scientific’s single‑use scopes and biliary stent systems, which hospitals adopt for ERCP and pancreaticobiliary interventions and cannot substitute without costly re‑training and regulatory hurdles. Category leadership translates into pricing power that sustains a 14.7% ROE despite a modest 0.5 debt‑to‑equity ratio, while the low‑beta (0.57) profile reflects a stable, recession‑resilient cash‑flow base.
Risk. The reverse‑DCF shows the market pricing in a -2% FCF growth rate for year 1, well below the 13.5% trailing revenue growth, signaling that investors fear a near‑term slowdown or margin compression. A P/E of 17.9, while reasonable, still implies earnings must accelerate to justify the upside, and the analyst target range’s low‑end ($44) suggests downside risk if growth decelerates or new competitive devices erode market share. A breach of the 52‑week low would confirm the bear case.
Horizon. 1-3 yr $61.00 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $89.31 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $132.49 if current growth sustains into durable earnings power.
24. ACN — Accenture plc · score 77.5
Information Technology Services · price $174.47 · 1Y $192.49 · 5Y $281.82 · 10Y $418.06
FCF $12.6b A- · Rev +6.7% C+ · D/E 0.25 B · P/E 13.9x A- · PEG 1.28 B
Why now. Accenture’s unrivaled depth in cloud‑enabled digital transformation drives a compounding engine that will keep earnings expanding. The firm’s 6.7% revenue growth and 10.7% profit margin are underpinned by a $12.6 B free‑cash‑flow base, while the Bull Rankings model awards a Quality score of 89 – the strongest pillar – confirming the business’s operational excellence. The thesis rests on the continued rollout of its intelligent platform and AI‑cloud services across Fortune‑500 clients, which should sustain the growth momentum.
Moat. Accenture’s moat lives in its end‑to‑end delivery network that couples strategy, systems integration and managed services, creating massive switching costs for global enterprises. Its ROE of 24.4% reflects pricing power derived from category leadership in AI‑cloud and industry‑specific platforms, a lever competitors can’t duplicate quickly without comparable scale and deep client relationships.
Risk. The bear case centers on the reverse‑DCF implied cash‑flow growth of –8% in year 1, well below the trailing 6.7% revenue growth, signaling that any slowdown could crush valuation. A modest beta of 1.09 amplifies market moves, and the P/E of 13.9, while reasonable, leaves little cushion if margin pressure or a dip in consulting spend materializes. A sustained decline in top‑line growth would validate the pessimistic growth assumption and trigger a price correction.
Horizon. 1-3 yr $192.49 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $281.82 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $418.06 if current growth sustains into durable earnings power.
25. AVGO — Broadcom Inc. · score 77.1
Semiconductors · price $349.57 · 1Y $531.85 · 5Y $778.68 · 10Y $1,155
FCF $39.4b A · Rev +48.7% A · D/E 0.60 C+ · P/E 44.5x C+ · PEG 0.35 A
Why now. Broadcom’s custom silicon for data‑center networking is the engine of compounding growth – it fuels a 48.7% revenue surge YoY while delivering a 42.9% profit margin and a massive $39.4 B free‑cash‑flow run‑rate. That triple‑threat of top‑line acceleration, margin depth and cash generation locks in a compounding runway that makes the stock a must‑own now.
Moat. The moat lives in Broadcom’s proprietary Ethernet switching, routing and NIC silicon that power the world’s hyperscale clouds; customers lock in multi‑year designs, giving Broadcom pricing power that translates into a ROE of 38.4% — a clear sign that its IP and scale command premium returns that rivals can’t replicate quickly.
Risk. The market still prices Broadcom at a lofty PE of 44.5 and a beta of 1.46, and our reverse‑DCF shows the current price assumes a year‑1 FCF growth of 41% – already below the trailing 48.7% revenue growth, signaling that any slowdown or margin compression would instantly invalidate the valuation. A breach of the 52‑week low at $289.96 would confirm the bear case.
Horizon. 1-3 yr $531.85 (analyst consensus (n=47)) — fundamentals + valuation re-rating. 5 yr $778.68 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $1,155 if current growth sustains into durable earnings power.
26. NFLX — Netflix, Inc. · score 77
Entertainment · price $69.23 · 1Y $92.93 · 5Y $136.05 · 10Y $201.83
FCF $11.2b A- · Rev +16.0% B+ · D/E 0.55 B+ · P/E 21.8x B · PEG 1.22 B
Why now. The single most compelling driver is Netflix’s unrivaled global streaming library that keeps subscribers glued to its platform, fueling a 16% revenue growth and a 28.2% profit margin while generating $11.2B of free cash flow. Our Bull Rankings model awards a Quality‑growth score of 77, with Quality as the strongest pillar, confirming the business’s high‑ROE engine (45.3%) and pricing power. The thesis rests on the ability to compound this cash‑rich growth into the next decade.
Moat. Netflix’s moat lies in its massive, data‑driven content catalog and seamless delivery across TVs, set‑top boxes, and mobiles, creating a switching cost for binge‑watchers who value instant access to diverse genres and languages. The 45.3% ROE reflects pricing power derived from category leadership in on‑demand streaming, a lever competitors struggle to replicate quickly.
Risk. The bear case centers on the elevated valuation: a forward P/E of 21.8 sits above the sector average, and the Bull Rankings model’s Value pillar (56) signals the stock is not cheap relative to peers. If subscriber growth stalls and the implied 28% year‑1 FCF growth fades faster than the 16% revenue pace, the price will be forced down, confirming the risk.
Horizon. 1-3 yr $92.93 (analyst consensus (n=45)) — fundamentals + valuation re-rating. 5 yr $136.05 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $201.83 if current growth sustains into durable earnings power.
27. VRT — Vertiv Holdings Co · score 76.8
Electrical Equipment & Parts · price $244.04 · 1Y $338.22 · 5Y $495.19 · 10Y $734.58
FCF $2.9b B · Rev +26.2% A- · D/E 0.70 B · P/E 55.1x D · PEG 0.85 B+
Why now. Vertiv’s dominance in mission‑critical power and thermal management for data centers fuels a compounding revenue engine – 26.2% YoY growth on a $2.9 B free‑cash‑flow base and a 15.1% profit margin that scales with capacity‑add cycles. The Bull Rankings model flags a Quality‑Growth score of 76.8, with Growth as the strongest pillar, underscoring the durability of this upside. The thesis rests on continued data‑center expansion that keeps Vertiv’s power‑and‑cooling solutions in relentless demand.
Moat. Vertiv’s integrated AC/DC power platforms and liquid‑cooled thermal systems lock in long‑term contracts with hyperscale cloud operators, creating high switching costs and pricing power that drives its 36.4% ROE. The breadth of its modular solutions—from single‑phase UPS to rack‑level distribution—means customers stay within a single vendor ecosystem, a moat that competitors can’t replicate quickly.
Risk. The stock trades at a lofty 55.1× forward earnings and a beta of 2.08, exposing it to market volatility and over‑optimistic pricing. Our reverse‑DCF shows the market assumes a 39% FCF growth rate in year 1—well above the trailing 26.2% revenue growth—so any slowdown would trigger a sharp re‑rating. A breach of the 52‑week low ($141.40) or a widening debt‑to‑equity above 0.7 would confirm the bear case.
Horizon. 1-3 yr $338.22 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $495.19 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $734.58 if current growth sustains into durable earnings power.
28. HALO — Halozyme Therapeutics, Inc. · score 76.4
Biotechnology · price $112.89 · 1Y $99.56 · 5Y $145.76 · 10Y $216.22
FCF $806m C+ · Rev +41.2% A · D/E n/a · P/E 33.1x C+ · PEG 1.56 C+
Why now. Biotechnology · market cap $12.8b. 3% off the 52-week high of $116.85. Revenue growing +41% — in hypergrowth territory. 9 sell-side analysts publish a mean 1-yr target of $99.56 (implying -12% upside).
Moat. Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 195% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk. Trailing P/E 33x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon. 1-3 yr $99.56 (analyst consensus (n=9)) — fundamentals + valuation re-rating. 5 yr $145.76 at ~5% CAGR — compounding case rests on the competitive position widening. 10 yr $216.22 if current growth sustains into durable earnings power.
29. WMG — Warner Music Group Corp. · score 76.3
Entertainment · price $27.14 · 1Y $37.75 · 5Y $55.27 · 10Y $81.99
FCF $836m C+ · Rev +12.9% B+ · D/E 4.53 D · P/E 21.7x B · PEG 0.49 A
Why now. Warner Music’s massive two‑million‑song catalog fuels a streaming‑driven revenue engine that is still expanding at 12.9% YoY, and the business converts that into an eye‑popping 78.7% ROE. Coupled with a sub‑1.0 PEG of 0.49 and a dividend hike signal, the company is set to compound cash flow for years, making the next 1‑3 years a pure growth play.
Moat. The Recorded Music and Publishing segments own and monetize an irreplaceable IP trove – roughly two million compositions – generating recurring royalties that competitors can’t replicate quickly. That deep rights base underpins the extraordinary ROE, giving Warner pricing power over streaming platforms and advertisers.
Risk. The stock trades at a forward‑looking P/E of 21.7 while carrying a debt‑to‑equity of 4.53 and a beta of 1.3, meaning any slowdown in the 13% FCF growth the market already assumes would slam the valuation. A missed dividend‑raise or a dip in streaming margins would confirm the bear case.
Horizon. 1-3 yr $37.75 (analyst consensus (n=16)) — fundamentals + valuation re-rating. 5 yr $55.27 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $81.99 if current growth sustains into durable earnings power.
30. CI — The Cigna Group · score 75.8
Healthcare Plans · price $271.83 · 1Y $341.83 · 5Y $500.48 · 10Y $742.43
FCF $9.1b B+ · Rev +11.3% B · D/E 0.74 C+ · P/E 11.2x A · PEG 0.74 A-
Why now. The Cigna Group’s Evernorth Pharmacy Benefit Services is set to capture deeper whole‑person health contracts, driving revenue that is already expanding at +11.3% YoY. Coupled with a robust free‑cash‑flow generation of $9.1 B and a PEG of 0.74, the business is priced at a modest PE of 11.2x, leaving ample upside. The bull case rests on the Bull Rankings model’s strongest pillar – Growth – which signals that this compounding revenue stream will keep accelerating.
Moat. Evernorth’s integrated pharmacy‑benefit‑management platform locks employers and health plans into a high‑touch network of formulary design, drug utilization review and home‑delivery services, creating switching costs that protect cash‑flow. The segment’s ROE of 16.8% reflects pricing power derived from its category‑leading data analytics and scale, which competitors cannot replicate quickly.
Risk. Despite the growth story, Cigna’s profit margin is a thin 2.3% and its debt‑to‑equity sits at 0.74, indicating limited headroom if cost pressures rise. The Bull Rankings model’s softest pillar – Quality – flags that the business’s low margin leaves little cushion, and a breach of the already modest margin would validate the bear view. A sustained margin contraction would trigger a price correction toward the 52‑week low.
Horizon. 1-3 yr $341.83 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $500.48 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $742.43 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.